期刊
NANO LETTERS
卷 20, 期 7, 页码 4857-4863出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.nanolett.0c00757
关键词
hypoxia; polypeptide nanoparticle; RNA interference; gene silencing; CDC20; cancer therapy
类别
资金
- National Institutes of Health (NIH) [CA200900]
- David Koch-PCF Award in Nanotherapeutics [201606170191, 201708320347]
- China Scholarship Council
- International Scientific and Technological Cooperation Program from Guangdong Science and Technology Department [2018A050506033]
As a hallmark of solid tumors, hypoxia promotes tumor growth, metastasis, and therapeutic resistance by regulating the expression of hypoxia-related genes. Hypoxia also represents a tumor-specific stimulus that has been exploited for the development of bioreductive prodrugs and advanced drug delivery systems. Cell division cycle 20 ( CDC20) functions as an oncogene in tumorigenesis, and we demonstrated the significant upregulation of CDC20 mRNA in the tumor vs paratumor tissues of breast cancer patients and its positive correlation with tumor hypoxia. Herein, a hypoxia-responsive nanoparticle (HRNP) was developed by self-assembly of the 2-nitroimidazole-modified polypeptide and cationic lipid-like compound for delivery of siRNA to specifically target CDC20, a hypoxia-related protumorigenic gene, in breast cancer therapy. The delivery of siCDC20 by HRNPs sufficiently silenced the expression of CDC20 and exhibited potent antitumor efficacy. We expect that this strategy of targeting hypoxia-correlated protumorigenic genes by hypoxia-responsive RNAi nanoparticles may provide a promising approach in cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据